ELAN has sold the European sales rights to its painkilling drug Prialt in a deal that could net the company €84 million.

Elan has agreed to sell the rights to its Prialt drug for the treatment of chronic pain in Europe to Eisai, while retaining the product rights in the United States.

Pharmaceutical firm Elan has sold its interests in anti-epileptic drug Zonegran to Eisai for $130m (€106.41m) if the deal is finalised by the end of April.